1. Active Lipid Management In Coronary Artery Disease (ALMICAD) Study
Sanjaya Khanal, MD, Omar Obeidat, MD, Michael P. Hudson, MD, Mouaz Al-Mallah, MD, Mary Bloome, PharmD, Mei Lu, PhD, Adam B. Greenbaum, MD, Aaron D. Kugelmass, MD, W. Douglas Weaver, MD 
The American Journal of Medicine 
Volume 120, Issue 8, Pages 734.e e17 (August 2007)
DOI: /j.amjmed
Copyright © 2007 Elsevier Inc. Terms and Conditions

2. Figure 1 Screening, enrollment, and follow-up.
The American Journal of Medicine  , 734.e e17DOI: ( /j.amjmed )
Copyright © 2007 Elsevier Inc. Terms and Conditions

3. Figure 2
Lipid clinic algorithm. FLPP=fasting lipid profile; ALT=alanine aminotransferase; D/C=discontinue; LDL=LDL cholesterol. %Statins: May substitute simvastatin with atorvastatin or pravastatin at equivalent doses. #Niacin (long acting): Start with 500 mg/d and increase as tolerated to 3 g/d. +Fibrates: fenofibrate 67 mg/d to maximum 200 mg/d; may substitute gemfibrozil 600 mg twice daily. ∧Bile acids: colesevelam 625 mg, 3 tablets twice per day with meals; may substitute cholestyramine or colestipol 2 to 6 scoops twice daily with meals.
The American Journal of Medicine  , 734.e e17DOI: ( /j.amjmed )
Copyright © 2007 Elsevier Inc. Terms and Conditions

4. Figure 3
Comparison of clinical outcomes at 2 years (%) between the groups. MACE=major adverse cardiac events, MI=myocardial infarction, PCI=percutaneous coronary intervention, CABG=coronary bypass surgery.
The American Journal of Medicine  , 734.e e17DOI: ( /j.amjmed )
Copyright © 2007 Elsevier Inc. Terms and Conditions

5. Figure 4
Kaplan-Meier major cardiovascular event-free survival curves. MACE=major adverse cardiac events.
The American Journal of Medicine  , 734.e e17DOI: ( /j.amjmed )
Copyright © 2007 Elsevier Inc. Terms and Conditions